Männedorf, Switzerland, December 4, 2025 – Tecan Group Ltd. (SIX Swiss Exchange: TECN) today announced that the Board of Directors will propose the following changes to shareholders for approval at ...

IV Sapu003 Reduces GI Exposure to Everolimus by 67-Fold Compared With Oral Dosing ...

Financing co-led by Kurma Partners and Curie Capital, includes strong line-up of European investors Matthew Baker appointed as CEO Laigo Bio’s SureTAC™ membrane protein degradation technology targets ...

Successful completion of private placement supported by existing and new shareholders raising EUR 5.1 million; extends cash runway well into Q3 2026, providing financial runway and flexibility to ...

Geneva, Switzerland, December 4, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric ...

Dr. Zahedi’s bestselling book, The Self-Made Maverick, continues to inspire entrepreneurs worldwide with lessons on resilience, risk-taking, and leadership.

MOORESVILLE, N.C., Dec. 03, 2025 (GLOBE NEWSWIRE) -- The Hemp Doctor, one of America’s leading hemp brands, announces the launch of its Fresh Bloom THCA Flower Subscription Box —delivering a curated ...

Hasan Shahid is the Founder and Chief Investment Officer of League Capital, a New York–based hedge fund specializing in technology, artificial intelligence, digital assets, and alternative investment ...

(NASDAQ: AXGN), a global leader in developing and marketing innovative surgical technologies for the restoration of peripheral nerve function, today announced that the U.S. Food and Drug ...

Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s Disease at the Clinical Trials on Alzheimer’s Disease (CTAD) ...

The Company intends to use the net proceeds from the Offering primarily for development activities, including the completion of its pivotal trial, and preparation of the PMA submission for GerlinC, ...

NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its participation at the ...